Examiner Cite

No

Initial*

Patent Number

Kind

publisher, city and/or country where published.

Code1

Issue Date

PTO/SB/08a (01-10) Approved for use through 07/31/2012 OMB 0651-0031 U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE io a collection of information unless it contains a valid OMB control number

Remove

Remove

Τ۶

Figures Appear

Pages.Columns.Lines where

Relevant Passages or Relevant

	Application Number		10581752
	Filing Date		2006-12-20
NFORMATION DISCLOSURE STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	First Named Inventor DEORE et a		RE et al.
	Art Unit		1766
	Examiner Name	FANC	S, SHANE
	Attorney Docket Number		17522NP

U.S. PATENTS

Name of Patentee or Applicant

of cited Document

ditional U.S. Patent cit	itation info	rmation ok					
	itation info	rmation pl					
U		pa	ease click the	Add button.		Add	
	J.S.PATEN	NT APPLIC	CATION PUBL	LICATIONS	R	emove	
	and Publicode ¹ Date	fication			olumns,Lines where Passages or Releva ppear		
ditional U.S. Published	ed Applicat	tion citation	n information p	lease click the Add	button.	Add	
	FOR	EIGN PAT	ENT DOCUM	ENTS	R	emove	
					or whe	ere Relevant ssages or Relevant	T5
ign	Document Co	FOR Document Country	FOREIGN PAT Document Country Kind	FOREIGN PATENT DOCUM Document Country Kind Publication	FOREIGN PATENT DOCUMENTS Document Country Kind Publication Name of Patentee Applicant of cited Pate.	FOREIGN PATENT DOCUMENTS R Document Country Kind Publication Applicant of cited Patential Paten	FOREIGN PATENT DOCUMENTS Remove Document Document Country Kind Publication Name of Patentee or Pages, Columns, Lines Pages, Columns,

NON-PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item

(book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s),

Examiner Cite

Initials* No INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10581752
Filing Date		2006-12-20
First Named Inventor DEOR		RE et al.
Art Unit		1766
Examiner Name FANG		S, SHANE
Attorney Docket Number		17522NP

1	European Patent Office, Examination Report for European Patent Application No. 04802260 2. Dated July 8, 2010.	
2	European Patent Office. Examination Report for European Patent Application No. 04802260.2. Dated August 2, 2011.	
3	Canadian Intellectual Property Office. Office Action for Canadian Patent Application No. 2,548,510. Dated October 4, 2011.	
4	E. Pringsheim et al. A Polyaniline with Near-Inflared Optical Response to Saochandes. Advanced Materials (1999) vol. 11 page 865.	
5	B. A. Decre et al. Conducting Poly(anilineboronic acid) Nanostructures: Controlled Synthesis and Characterization. Macromol. Chem. Phys. (2008) vol. 299 pages 1094-1105.	
6	J. T. English et al. Biogenic amme vapour detection using poly(antimeboronic acid) films. Sensors and Actuators B. (2006) vol. 115, pages 666-671.	
7	B. A. Deore et al. Macromol. Chem. Phys. pH Dependent Equilibris of Poly(antilineboronic acid). Saccharide Complexation in Thiri Films (2006) vol. 207, pages 690-664.	
8	I. Yu et al. Thermal Stability of High Molecular Weight Self-Doped Poly(anilineboronic acid), Macromolecules (2005) vol. 38 pages 10022-10026.	
9	B.A. Decre et al. Reactivity of Poly(antineboronic acid) with NAD and NADH. Chem. Mater. (2005) vol.17 pages 2918-2923.	
10	C.L. Recksedier et al. Substitution and Condensation Reactions with Poly(antimeboronic acid). Reactivity and Characterization of Thin Films. Langmuir (2005) vol. 21 pages 3670-3674	
11	B. A. Deore et al. Electroactivity of Electrochemically Synthesized Poly/Aniline Boronic Acid) as a Function of pH. Role of Self-Doping. Chem. Mater. (2004) vol. 16 pages 1427-1432.	

	12	E. Shoji et al. Potentiometric Sensors Based on the Inductive Effect on the pKs of Poly(antline). A Nonenzymatic Glucose Sensor, J. Am. Chem. Soc. (2001) vol. 123, pages 3383-3384.	
	13	E. Shoj et al. Poly(aniline boronic acid): A New Precursor to Substituted Poly(aniline)s, Langmur (2001) vol. 17 number 23.	
If you wisl	h to a	dd additional non-patent literature document citation information please click the Add button Add	1

Examiner Signature Date Considered Date Considered |

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Codes of USPTO Patent Documents at <u>www.USPTO.GDV</u> or MPEP 901 DL. ² Entire office that issued the document, by the two-letter code (WIPO Standard ST 3). ³ For Japanese peter documents, the adulation of the year of the steps of the Circumstant and adulation of the year of the steps of the Circumstant and the See adulation of the peter document. ³ Wind of document by the papproprise synthesis as adulation to the document under WIPO Securities 201. ³ Applicant to be place a check man here the Mind of Comment and the WIPO Securities 201. ³ Applicant to be passed as whether the Mind of Comment and the WIPO Securities 201. ³ Applicant to be passed as whether the Mind of Comment and Mind of Comment and

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10581752		
Filing Date		2006-12-20		
First Named Inventor	DEORE et al.			
Art Unit		1766		
Examiner Name	FANG	S, SHANE		
Attorney Docket Number		17522NP		

CERTIFICATION STATEMENT

Please see 37	CFR 1.9	7 and 1.98 to	make the appropriate	selection(s	:)
---------------	---------	---------------	----------------------	-------------	----

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e/t1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.57(c).

- See attached certification statement.
- The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- A certification statement is not submitted herewith

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Alyssa Ann Finamore/	Date (YYYY-MM-DD)	2011-11-09
Name/Print	Alvesa Ann Finamore	Registration Number	55177

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1445, Alexandrin, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandria, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the stackhold from reliable to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. (2)(2)(2) familishing of the information solicided is columbrary, and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested more considerable or the patient of the patient of

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the sublect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, ourspant to 5 U.S.C. S52a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, during an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of
 the application presume to 58 U.S. C. 12(p) or issuance of a patent pursuant to 58 U.S. C. 151. Further, a record
 may be disclosed, subject to the limitations of 37 CFR 11, 4s as routine use, to the public if the record was filed in
 an application which became abandoned or in which the proceedings were terminated and which application is
 referenced by whither a published application is application open to public inscredions or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.